Sun Sep 15 13:36:29 UTC 2024: ## Bristol Myers Squibb Reports Record-Breaking 10-Year Survival Rates for Melanoma Patients Treated with Opdivo and Yervoy
**Barcelona, Spain – September 14, 2024** – Bristol Myers Squibb (NYSE: BMY) today announced groundbreaking 10-year follow-up data from the CheckMate-067 clinical trial, demonstrating sustained and durable improvement in survival for patients with advanced melanoma treated with Opdivo® (nivolumab) plus Yervoy® (ipilimumab). This data, presented at the European Society for Medical Oncology (ESMO) Congress 2024 and published in The New England Journal of Medicine, represents the longest reported median overall survival from a Phase 3 advanced melanoma trial.
The study revealed that after 10 years, over 40% (43%) of patients treated with Opdivo plus Yervoy were still alive. A decade ago, the survival rate for this patient population was only around 25% after just one year.
“These data continue to demonstrate the impressive and durable clinical benefit of nivolumab in combination with ipilimumab,” said Dr. James Larkin, Consultant Medical Oncologist at The Royal Marsden. “Remarkably, 43% of patients treated with nivolumab and ipilimumab are alive ten years later and many did not need subsequent therapy.”
The combination therapy also showed significant improvement in melanoma-specific survival, with 52% of patients still alive at 10 years, compared to 44% for Opdivo alone and 23% for Yervoy alone.
“Just over a decade ago, an advanced melanoma diagnosis meant that you likely only had months to live,” said Dr. Dana Walker, vice president, global program lead, melanoma and gastrointestinal and genitourinary cancers at Bristol Myers Squibb. “The dual immunotherapy combination of Opdivo plus Yervoy has radically changed this outlook for many of these patients. Our goal was, and still is, to redefine survival expectations for patients with melanoma; these data demonstrate our commitment to that objective and continue to provide hope.”
The safety profile of Opdivo plus Yervoy was consistent with previous findings, with no new safety signals observed.
These findings represent a significant milestone in the fight against melanoma, offering a glimmer of hope for patients diagnosed with this devastating disease.
First Piper 